This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Question Revisited

Helena Chmura Kraemer, PhD; Jared Tinklenberg, MD; Jerome A. Yesavage, MD

Arch Neurol. 1994;51(3):275-279.

Abstract
Objective
To expand on a recent study of 42 patients with probable Alzheimer's Disease that found that the only significant predictors of certain clinical end points were the degree of severity features at entry ("how far").

Design
A case series study of a cohort of 81 patients with Alzheimer's disease that used survival analysis methods similar those of the previous study but included a new technique for calculating rate of progression ("how fast") as well as entry characteristics ("how far").

Setting
A university medical center and its affiliated Veterans Affairs Medical Center.

Patients
All patients with probable and definite Alzheimer's disease studied at the Aging Clinical Research Center at Stanford University, Palo Alto, Calif, in the years 1981 and 1992 who met the following criteria: a mild to moderate level of severity of the disease (Mini—Mental State Examination score of 15 or above) at entry into the study and a minimum of three test points spaced approximately 6 months apart (to allow estimation of rate of progression). A total of 81 such patients were identified. These patients had been followed up for a mean of 4.53±2.3 years, with a range of 1.0 to 14.5 years. Main Outcome Measure: The outcome measure was the average rate of decline on the Mini—Mental State Examination.

Results
The results of our study replicated a previous finding that the degree of severity is a strong predictor of time course, but in addition we found that the rate of progression also appears to be a strong predictor of clinical course.

Conclusion
There appears to be substantial heterogeneity in the rate of progression in patients with Alzheimer's disease, and, like initial degree of severity, rate of progression appears to be a strong predictor of clinical course.

Author Affiliations
From the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine and Veterans Affairs Medical Center, Palo Alto, Calif.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Whole-brain atrophy rate in Alzheimer disease: Identifying fast progressors
Sluimer et al.
Neurology 2008;70:1836-1841.
ABSTRACT | FULL TEXT  

Mediterranean diet and Alzheimer disease mortality
Scarmeas et al.
Neurology 2007;69:1084-1093.
ABSTRACT | FULL TEXT  

Motor signs predict poor outcomes in Alzheimer disease
Scarmeas et al.
Neurology 2005;64:1696-1703.
ABSTRACT | FULL TEXT  

Motor signs during the course of Alzheimer disease
Scarmeas et al.
Neurology 2004;63:975-982.
ABSTRACT | FULL TEXT  

Predicting the rate of cognitive decline in aging and early Alzheimer disease
Adak et al.
Neurology 2004;63:108-114.
ABSTRACT | FULL TEXT  

Extrapyramidal symptoms and signs in Alzheimer's disease: Pravalence and correlation with the first symptom
Tsolaki et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2001;16:268-278.
ABSTRACT  

Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression
Farlow et al.
Arch Neurol 2001;58:417-422.
ABSTRACT | FULL TEXT  

A Method for Estimating Progression Rates in Alzheimer Disease
Doody et al.
Arch Neurol 2001;58:449-454.
ABSTRACT | FULL TEXT  

Extrapyramidal Signs in Patients With Probable Alzheimer Disease
Lopez et al.
Arch Neurol 1997;54:969-975.
ABSTRACT  

A Family Intervention to Delay Nursing Home Placement of Patients With Alzheimer Disease: A Randomized Controlled Trial
Mittelman et al.
JAMA 1996;276:1725-1731.
ABSTRACT  

Apolipoprotein E E4 Allele and Risk of Dementia-Reply
Frisoni et al.
JAMA 1995;273:375-376.
ABSTRACT